TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
1. An isolated fusion protein comprising an IgV-like domain of a TMIGD2 and an Fc portion of an immunoglobulin G, wherein the isolated fusion protein comprises SEQ ID NO:2 or SEQ ID NO:3.
2. The isolated fusion protein of claim 1 , comprising SEQ ID NO:2.
3. The isolated fusion protein of claim 1 , comprising SEQ ID NO:3.
4. An isolated chimeric nucleic acid encoding the isolated fusion protein of claim 1 .
5. A composition comprising the isolated fusion protein of claim 1 and a carrier.
6. The composition of claim 5 , which is a pharmaceutical composition, and wherein the carrier is a pharmaceutical carrier.